Free Trial

CytomX Therapeutics (CTMX) News Today

CytomX Therapeutics logo
$0.59 -0.04 (-5.60%)
As of 11:10 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Up 91.5% in March
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 9,000,000 shares, an increase of 91.5% from the February 28th total of 4,700,000 shares. Approximately 12.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,790,000 shares, the short-interest ratio is presently 5.0 days.
CytomX Therapeutics, Inc. stock logo
Insider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Sells 19,512 Shares of Stock
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) SVP Marcia Belvin sold 19,512 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $0.60, for a total transaction of $11,707.20. Following the completion of the sale, the senior vice president now directly owns 248,636 shares in the company, valued at $149,181.60. This trade represents a 7.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
CytomX Therapeutics, Inc. stock logo
Sean A. Mccarthy Sells 37,656 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) CEO Sean A. Mccarthy sold 37,656 shares of CytomX Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $0.60, for a total value of $22,593.60. Following the sale, the chief executive officer now owns 995,195 shares in the company, valued at $597,117. This represents a 3.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by StockNews.com
StockNews.com raised shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a research report on Monday.
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics (NASDAQ:CTMX) Given "Outperform" Rating at Wedbush
Wedbush reaffirmed an "outperform" rating and set a $5.00 price objective on shares of CytomX Therapeutics in a report on Friday.
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by Brokerages
Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and three have assigne
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday
CytomX Therapeutics (NASDAQ:CTMX) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=351571)
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics (NASDAQ:CTMX) Share Price Crosses Below 50-Day Moving Average - Here's What Happened
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50-Day Moving Average - What's Next?
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below 50 Day Moving Average - Should You Sell?
CytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below 50 Day Moving Average - Here's What Happened
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from Brokerages
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company.
CytomX Therapeutics, Inc. stock logo
Assenagon Asset Management S.A. Sells 1,044,318 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)
Assenagon Asset Management S.A. reduced its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 63.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 599,850 shares of the biotechnology company'
CytomX Therapeutics, Inc. stock logo
Short Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Drops By 13.4%
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 4,800,000 shares, a decline of 13.4% from the December 15th total of 5,540,000 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is currently 3.9 days.
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and three have given a buy ratin
Piper Sandler Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)
CytomX Therapeutics (CTMX) Gets a Buy from Barclays
CytomX Therapeutics (CTMX) Receives a Buy from Wedbush
CytomX Therapeutics to Cut 40% of Workforce
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics (NASDAQ:CTMX) Receives "Neutral" Rating from HC Wainwright
HC Wainwright reissued a "neutral" rating on shares of CytomX Therapeutics in a research report on Tuesday.
CytomX Therapeutics, Inc. stock logo
Short Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Expands By 26.2%
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 5,540,000 shares, a growth of 26.2% from the November 30th total of 4,390,000 shares. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is presently 4.8 days.
CytomX heading into ‘major catalyst year,’ says JonesResearch
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from Analysts
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have assign
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below Two Hundred Day Moving Average - Time to Sell?
CytomX Therapeutics (NASDAQ:CTMX) Share Price Crosses Below 200-Day Moving Average - What's Next?
CytomX Therapeutics, Inc. stock logo
Janus Henderson Group PLC Has $5.70 Million Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX)
Janus Henderson Group PLC decreased its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 23.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,809,518 shares
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 21.7% in November
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 4,440,000 shares, a decline of 21.7% from the October 31st total of 5,670,000 shares. Based on an average daily volume of 809,100 shares, the short-interest ratio is currently 5.5 days.
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from Brokerages
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy
CytomX Therapeutics, Inc. stock logo
Research Analysts Set Expectations for CTMX FY2024 Earnings
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Analysts at HC Wainwright raised their FY2024 earnings estimates for shares of CytomX Therapeutics in a report issued on Monday, November 11th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will post earnings per
CytomX Therapeutics, Inc. stock logo
CytomX Therapeutics (NASDAQ:CTMX) Share Price Passes Below Fifty Day Moving Average - Here's Why
CytomX Therapeutics (NASDAQ:CTMX) Share Price Passes Below 50-Day Moving Average - Here's Why
Q3 2024 CytomX Therapeutics Inc Earnings Call
CytomX Therapeutics Reports Q3 Progress and Growth
CytomX Therapeutics (CTMX) Receives a Buy from Barclays
Remove Ads
Get CytomX Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

CTMX Media Mentions By Week

CTMX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CTMX
News Sentiment

0.94

0.82

Average
Medical
News Sentiment

CTMX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CTMX Articles
This Week

3

2

CTMX Articles
Average Week

Remove Ads
Get CytomX Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CTMX) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners